The market of cancer screening is observing a
speedy upsurge owing to a speedy increase in the number of cancer cases. There
lies an instantaneous requirement to seek the early diagnosis and the
preventative procedures. The growth of the market lies in the acceptance of the
innovative screening technologies to accommodate to the cause. The high-scale
contribution are being accepted by the individuals on the diagnostics
instruments along with the collaboration with the legal authorities to ensure
the instrument obtainability.
Although, on the basis of type and end users,
the worldwide cancer screening market is sectored into hospitals, laboratory,
independent physicians and clinics whereas types are laboratory, genetic,
imaging, biopsy, and endoscopy. Not only has this, the sector of the
application includes lung, breast, kidney, melanoma and colorectal.
According to the report analysis, ‘Global
Cancer Screening Market (2018-2023)’ states that in the market of
cancer screening, there are numerous key players which are recently performing
their task or job more positively and actively for leading the fastest market
growth and dominating the high value of market share across the globe in the
coming years while advancing the technologies of diagnostic, delivering the
effective and benefitted services, improving the applications and benefits of
the economic technologies and providing the high level of the consumer
satisfaction includes GE Healthcare, Siemens Healthineers, Abbott Diagnostics,
F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Hologic Inc., Becton,
Dickinson and Company, Qiagen, Philips, Illumina and several others.
Although, based on the geography, the market
of cancer screening is spread across the globe which majorly involves North
America, Asia Pacific region, Europe, South Africa and rest of the globe.
Whereas, North America and Europe will be the leading economies for the market.
Asia-Pacific is the fastest increasing region for the cancer screening market
while Latin America demands to function on its economic scenario to fulfil the
region's growing demand for cancer diagnosis.
Meanwhile, there lies a causal threat to
deliver the affordable and reachable treatment to all. Along with this
delivering the transparency and safety of medical processes will be a key
challenge for the cancer screening market. In addition, the effective growth in
the number of cancer cases and increasing awareness among individual to seek
preventive measures along with government-centered ingenuities towards cancer
prevention is fueling the cancer screening market. Prevention calls for
groundbreaking methodologies and technologies to be reachable for early
diagnosis.
Additionally, ‘Liquid biopsy’ is one of the
modern technology emerging in the market which would support in the early
recognition of several cancers by scanning for DNA fragments which are shed by
tumor cells. The potential corporates such as SRBI healthcare, GRAIL Inc., and
others are nurturing funds for early diagnosis of cancer. In present trend, the
Next Generation Sequencing (NGS) is being extensively utilized for the
detection of numerous types of cancer. NGS enables the simultaneous sequencing
of targeted genomic locations in multiple samples to determine or monitor the
mutations. The main benefit of this method is the requirement of low amount of
DNA or RNA. Therefore, in the coming years, it is anticipated that the market
of cancer screening will increase across the globe more positively over the
coming years more enormously.
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91
9015378249
